Head-to-head · free
iRhythm Technologies, Inc. vs Eli Lilly
IRTC vs LLY — return on capital, cash generation, margins and balance sheet side by side.
IRTC
2 / 7
measures where IRTC leads
LLY
5 / 7
measures where LLY leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | IRTC · FY2025 | LLY · FY2025 |
|---|---|---|
| Revenue | $747.1M | $65.2B |
| Net income | (44.6M) | $20.6B |
| Revenue growth (yearly, multi-year) | 23.3% | 23.2% |
| Free cash flow | $34.5M | — |
| Free cash flow margin | 4.6% | — |
| Net cash / (debt) | — | — |
| ROIC | — | 36.1% |
| Return on equity | -36.6% | 101.4% |
| Gross margin | 70.6% | 83.0% |
| Operating margin | -6.7% | 45.6% |
| Net debt / EBITDA | -13.37x | 1.25x |
Figures are as reported by each company; latest fiscal year shown.
Where iRhythm Technologies, Inc.'s cash went (FY2025)
- Capital spending
- $46.3M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Eli Lilly's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free